Co-Morbidity and COVID-19: A Study of Case Severity and Early Outcome

Rohit Patawa, Ankita Goyal, N. Tiwari
{"title":"Co-Morbidity and COVID-19: A Study of Case Severity and Early Outcome","authors":"Rohit Patawa, Ankita Goyal, N. Tiwari","doi":"10.29333/jcei/11583","DOIUrl":null,"url":null,"abstract":"Background: The corona virus disease 2019 (COVID-19) has spread around the world and mutating rapidly. It is absolutely essential to evaluate the potential risk factor influencing disease progression and better understanding of high risk co-morbidities among COVID-19 patients. Objectives: To evaluate the association of serious events in COVID-19 patients according to the number and type of co-morbidities also the association of co-morbidities with the adverse events and the risk of early outcomes with any co-morbidity. Methods: This was a prospective observational study among 1,583 laboratory-confirmed COVID-19 cases admitted during the study period from Apr 2020 to March 2021. Odds ratio (OR) and risk ratio (RR) with respective confidence intervals have been calculated to evaluate the presence and strength of association of case severity with the presence and number of co morbidities. Results: There was 302 study subjects with one or more than one co-morbidities having the mean (SD) age of 54(15) year and 206(68.2%) male cases compared to female. The leading comorbidities were diabetes (146, 9.2%), hypertension (142, 9%) with respiratory disease (50, 3.2%), CAD (16, 1%). Any co-morbid patient has 6 times odds of getting admitted in ICU in comparison to non-co-morbid patient while the risk ratio signifies that five times higher chance of getting admitted in ICU than any non-co-morbid patient. The chances of death in them are always higher than non-co-morbid specially diabetes and hypertensive with CAD. Conclusions: Among patients with COVID-19 disease any co-morbidity resulted to poorer clinical outcomes and more the number of co-morbidities, poorer the clinical outcomes. [ FROM AUTHOR];Copyright of Journal of Clinical & Experimental Investigations is the property of Modestum Publications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)","PeriodicalId":53255,"journal":{"name":"Journal of Clinical and Experimental Investigations","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2022-01-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical and Experimental Investigations","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.29333/jcei/11583","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Background: The corona virus disease 2019 (COVID-19) has spread around the world and mutating rapidly. It is absolutely essential to evaluate the potential risk factor influencing disease progression and better understanding of high risk co-morbidities among COVID-19 patients. Objectives: To evaluate the association of serious events in COVID-19 patients according to the number and type of co-morbidities also the association of co-morbidities with the adverse events and the risk of early outcomes with any co-morbidity. Methods: This was a prospective observational study among 1,583 laboratory-confirmed COVID-19 cases admitted during the study period from Apr 2020 to March 2021. Odds ratio (OR) and risk ratio (RR) with respective confidence intervals have been calculated to evaluate the presence and strength of association of case severity with the presence and number of co morbidities. Results: There was 302 study subjects with one or more than one co-morbidities having the mean (SD) age of 54(15) year and 206(68.2%) male cases compared to female. The leading comorbidities were diabetes (146, 9.2%), hypertension (142, 9%) with respiratory disease (50, 3.2%), CAD (16, 1%). Any co-morbid patient has 6 times odds of getting admitted in ICU in comparison to non-co-morbid patient while the risk ratio signifies that five times higher chance of getting admitted in ICU than any non-co-morbid patient. The chances of death in them are always higher than non-co-morbid specially diabetes and hypertensive with CAD. Conclusions: Among patients with COVID-19 disease any co-morbidity resulted to poorer clinical outcomes and more the number of co-morbidities, poorer the clinical outcomes. [ FROM AUTHOR];Copyright of Journal of Clinical & Experimental Investigations is the property of Modestum Publications and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full . (Copyright applies to all s.)
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
合并症与COVID-19:病例严重程度和早期结局的研究
背景:2019冠状病毒病(COVID-19)已在全球传播并迅速变异。评估影响疾病进展的潜在危险因素和更好地了解COVID-19患者的高风险合并症是绝对必要的。目的:根据合并症的数量和类型来评估COVID-19患者严重事件的相关性,以及合并症与不良事件的相关性以及早期结局与合并症的风险。方法:对2020年4月至2021年3月期间收治的1583例实验室确诊的COVID-19病例进行前瞻性观察研究。计算了各自置信区间的优势比(OR)和风险比(RR),以评估病例严重程度与合并症的存在和数量之间存在的关联及其强度。结果:302名研究对象有一种或一种以上的合并症,平均(SD)年龄为54(15)岁,男性206例(68.2%),女性206例(68.2%)。主要合并症为糖尿病(146例,9.2%)、高血压(142例,9%)合并呼吸系统疾病(50例,3.2%)、冠心病(16.1%)。合并症患者入住ICU的几率是非合并症患者的6倍,而风险比表明合并症患者入住ICU的几率是非合并症患者的5倍。冠心病的死亡率高于非合并症,特别是糖尿病和高血压。结论:在COVID-19患者中,任何合并症均导致临床预后较差,合并症数量越多,临床预后越差。[来自作者];Journal of Clinical & Experimental Investigations版权归Modestum Publications所有,未经版权所有者明确书面许可,不得将其内容复制或通过电子邮件发送到多个网站或发布到listserv。但是,用户可以打印、下载或通过电子邮件发送文章供个人使用。这可以删节。对副本的准确性不作任何保证。用户应参阅原始出版版本的材料的完整。(版权适用于所有人。)
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
25
期刊最新文献
Clinical characteristics and hospitalization factors in pneumothorax patients: Clinical and therapeutic perspectives from Souss Massa Region Comparison of serum and salivary creatinine levels in preterm neonates High mobility box protein-1 may be a new biomarker in active interstitial lung disease of systemic sclerosis Modified Roux-Goldthwait procedure for habitual patellar dislocation in pediatric population Anti-angiogenic and oxidative effects of sodium benzoate at different concentrations in chorioallantoic membrane model
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1